Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hormonal therapies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    405 result(s) found for: Hormonal therapies. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-003654-15 Sponsor Protocol Number: 080314 Start Date*: 2008-09-22
    Sponsor Name:Karolinska University Hospital
    Full Title: Oral 1 mg oestradiol (E2) / 2 mg of drosperinone (DRSP) and 1 mg of oestradiol / 0.5 mg of norethisteroneacetate (NETA): effects on mammografic density and breast epithelial proliferation - an expl...
    Medical condition: The effect of hormonal treatment on mammographic density and breast epithelial proliferation in postmenopausal women.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020422 HRT LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001185-10 Sponsor Protocol Number: 14I/Prg02 Start Date*: 2014-09-08
    Sponsor Name:IBSA Institut Biochimique SA
    Full Title: Effect of a progesterone 25 mg solution (Pleyris, IBSA Farmaceutici Italia, srl) administered by oral route compared to an oral progesterone 200 mg capsule (Prometrium, Rottapharm SpA) on the endom...
    Medical condition: hormone replacement therapy of menopause (as progestin therapy in association to estrogen replacement therapy)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10020388 Hormone replacement therapy PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005109-23 Sponsor Protocol Number: AWC LowE Start Date*: 2009-08-05
    Sponsor Name:Uppsala University Hospital
    Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound.
    Medical condition: Age/menopause related changes in the artery wall composition after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    9.1 10051775 Postmenopause LLT
    9.1 10020388 Hormone replacement therapy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000265-67 Sponsor Protocol Number: APR-486 Start Date*: 2017-08-01
    Sponsor Name:Aprea Therapeutics AB
    Full Title: PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
    Medical condition: Platinum-resistant high grade serous ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-004631-92 Sponsor Protocol Number: WWU20_0041 Start Date*: 2022-07-26
    Sponsor Name:Westfälische Wilhelms-Universität Münster, C/o Universitätsklinikum Münster Geschäftsbereich Recht u. Drittmittel
    Full Title: Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma
    Medical condition: recurrence of glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000319-41 Sponsor Protocol Number: RPC01-3101 Start Date*: 2015-09-18
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
    Medical condition: ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) NL (Completed) GB (Completed) BE (Completed) BG (Completed) PL (Completed) HR (Completed) LV (Completed) AT (Completed) GR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002036-32 Sponsor Protocol Number: C3441006(MDV3800-06) Start Date*: 2016-12-05
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO 1: A PHASE 2, OPEN LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE BASED CHEMOTHE...
    Medical condition: Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) ES (Ongoing) FR (Completed) BE (Completed) GB (Completed) AT (Completed) DK (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022239-12 Sponsor Protocol Number: ISIS 183750-CS3 Start Date*: 2011-05-05
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), inPatients with Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-017671-22 Sponsor Protocol Number: E7389-G000-398 Start Date*: 2010-07-15
    Sponsor Name:Eisai Limited
    Full Title: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies
    Medical condition: Advanced and/or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006198 Breast cancer recurrent LLT
    12.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001472-38 Sponsor Protocol Number: APR-407 Start Date*: 2013-12-12
    Sponsor Name:Aprea Therapeutics AB
    Full Title: PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Withou...
    Medical condition: Recurrent high grade serous ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021045 10033131 Ovarian carcinoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Completed) SE (Completed) ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004533-34 Sponsor Protocol Number: BIOV-221 Start Date*: 2005-05-19
    Sponsor Name:Bioenvision
    Full Title: A Phase IV Non-randomised Study of Modrenal® (Trilostane) in Post-menopausal Women with Advanced, Oestrogen Receptor Positive Breast Cancer for whom Prior Endocrine Therapies have Failed, One of w...
    Medical condition: Advanced, Oestrogen Receptor Positive Breast Cancer for whom Prior Endocrine Therapies have Failed, One of which was an Aromatase Inhibitor
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003201-14 Sponsor Protocol Number: ERTUSO Start Date*: 2012-03-02
    Sponsor Name: Krankenhaus Nordwest GmbH
    Full Title: Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-...
    Medical condition: Patients with HER2/neu (1+/SISH positive, 2+ and 3+) expressing solid tumors that are progressing after standard therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005387-25 Sponsor Protocol Number: noprofit1616 Start Date*: 2016-05-05
    Sponsor Name:Sapienza, University of Rome
    Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
    Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10045172 Tumour vaccine therapies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000380-13 Sponsor Protocol Number: CP-MGAH22-04 Start Date*: 2015-09-02
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 The...
    Medical condition: Metastatic or Locally Advanced HER2-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) CZ (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001305-23 Sponsor Protocol Number: 20190505 Start Date*: 2021-09-15
    Sponsor Name:Amgen
    Full Title: A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006686-17 Sponsor Protocol Number: P05094 Start Date*: 2007-04-25
    Sponsor Name:Schering-Plough
    Full Title: Evaluation of preference for a buprenorphine-based maintenance therapy, after a switch from buprenorphine alone (Subutex®) to the buprenorphine/naloxone combination (Suboxone®), in opioid-dependent...
    Medical condition: For both compounds, substitution treatment for opiod drug dependence, adult subjects with a diagnosis of major heroin dependence. Only for Suboxone, the intention of naloxone is to deter the intrav...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005544-17 Sponsor Protocol Number: EMR 200038-010 Start Date*: 2009-08-20
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy...
    Medical condition: post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Completed) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) SK (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005024-42 Sponsor Protocol Number: TCP-102 Start Date*: 2014-06-18
    Sponsor Name:Menlo Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis
    Medical condition: Pruritus nodularis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001559-38 Sponsor Protocol Number: GEICAM/2018-06 Start Date*: 2022-01-20
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Can...
    Medical condition: HER2+, HR+ Early stage Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083234 Hormone receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 14 15:04:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA